References

  1. What is Hemophilia? In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:1-1 to 1-24.
  2. Bleeding Episodes. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:3-1 to 3-29.
  3. Complications of Hemophilia. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:4-1 to 4-25.
  4. Arun B, Kessler CM. Clinical Manifestations and Therapy of the Hemophilias. In: Colan RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:815-824.
  5. Feinstein DI. Inhibitors in Hemophilia. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:1904-1911.
  6. Dental and Oral Care. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:5-1 to 5-13.
  7. Feinstein DI. Inhibitors of Blood Coagulation. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000: 1963-1983.
  8. Physical Activity. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:6-1 to 6-16.
  9. National Hemophilia Foundation. "Do the 5" Program. Available at: http://www.hemophilia.org/programs/npp/npp.htm. Accessed June 20, 2008.
  10. DiMichele DM. Inhibitors in Hemophilia: a Primer. Treatment of Hemophilia Monograph Series; Number: World Federation of Hemophilia: 1007, revised 2000.
  11. Ewing, NP. Induction of immune tolerance, the future of the Registry. Vox Sang. 1996;70(suppl 1):47-51.
  12. Mariani, G Ghiradini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Thromb Haemost. 1994;72:155-158
  13. Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII—a critical appraisal. Haemophilia. 2006;12(1):19-27
  14. Lusher JM, Roberts HT, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia. 1998;4:790-798.
  15. Data on file. Novo Nordisk Inc.
  16. Sakai T, Lund-Hansen T, Thim L, Kisiel W. The gamma-carboxyglutamic acid domain of human factor VIIa is essential for its interaction with cell surface tissue factor. J Biol Chem 1990; 265: 1890-1894.
  17. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958-965.
  18. Hoffman M, Monroe DM, Roberts HR. Activated Factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9 (suppl 1):s61-s65.
  19. Data on file. Integrated Summary of Safety. [1997:103]. Novo Nordisk Inc.
  20. Nicolaisen EM, Hansen LL, Poulsen F. Immunological aspects of recombinant factor VII (rFVIIa) in clinical use. Thromb Haemost. 1996;76:200-204.
  21. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998; 80(5):773-778.
  22. Woolhouse MEJ, Gowtage-Sequeria S, Evans B. Quantitative analysis of the characteristics of emerging and re-emerging human pathogens (T-16). Available at: www.foresight.gov.uk. Accessed June 20, 2008.
  23. National Heart, Lung, and Blood Institute. Morbidity & Mortality: 2004 Chartbook on Cardiovascular, Lung, and Blood Diseases. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD. 2004:5.
  24. National Hemophilia Federation. National Hemophilia Federation bleeding page. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=43&contentid=39&rptname=bloodsafety. Accessed June 5, 2006.
  25. Medical and Scientific Advisory Council. MASAC Recommendation #169: Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission.
  26. Brackmann H-H, Effenberger E, Hess L, et al. Immune Tolerance Induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol 1998: 61(suppl 63):18-23.
  27. Giangrande P. Acquired Hemophilia. World Federation of Hemophilia; 2005. Treatment of Hemophilia [monograph] No. 38.
  28. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;45:200-203.
  29. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
  30. Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol. 2000;22:275-278.
  31. Cohen AJ, Kessler CM. Acquired inhibitors. Bailleres Clin Haematol. 1996;9:331-354.
  32. NovoSeven [package insert]. Princeton, NJ: Novo Nordisk Inc; 2006.
  33. Collins PW, Hirsch S, Baglin TP, et al; for UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007;109(5):1870-1877.
  34. Anderson A, Forsyth A. Playing it safe: bleeding disorders, sports and exercise. New York: National Hemophilia Foundation, 2005.
  35. Nursing Group of Hemophilia Region VI. Emergency care for patients with hemophilia. Last Update 2003. Available at: http://www.hemophiliaemergencycare.com/index.html Accessed April 28, 2008.
  36. Ding C, Cicuttini F, Scott F, et al. Knee structural alteration and BMI: a cross-sectional study. Obes Res 2005; 13:350-61.
  37. Messier SP, Gutekunst DJ, Davis C, et al. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum 2005; 52:2026-32.
  38. NovoSeven® RT [package insert]. Princeton, NJ: Novo Nordisk Inc.; 2008
  39. FEIBA (anti-inhibitor coagulant complex, vapor-heated) package insert. Westlake Village, CA; Baxter Healthcare Corporation; 2000.
  40. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5: 893-900.